<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00116779</url>
  </required_header>
  <id_info>
    <org_study_id>FE200486 CS14</org_study_id>
    <nct_id>NCT00116779</nct_id>
  </id_info>
  <brief_title>A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer</brief_title>
  <official_title>An Open-label, Randomized, Multi-center, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer Dosed for Thirteen 28-day Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to contribute, along with other such dose-finding studies, to
      the identification of the most effective treatment regimen for a one month depot injection of
      degarelix in the treatment of prostate cancer by a rapid and sustained suppression of
      testosterone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Testosterone &lt;=0.5 Nanogram/Milliliter From Day 28 to Day 364</measure>
    <time_frame>Day 28 to Day 364</time_frame>
    <description>Number of participants with all testosterone values &lt;=0.5 nanogram/milliliter from Day 28 to Day 364</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Testosterone Level &lt;= 0.5 Nanogram/Milliliter From Day 28 to Day 364 for Participants With Testosterone &lt;= 0.5 Nanogram/Milliliter at Day 28</measure>
    <time_frame>Day 28 - Day 364</time_frame>
    <description>Number of participants who maintained a testosterone level of &lt;=0.5 nanogram/milliliter from Day 28 to Day 364.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Testosterone &lt;= 0.5 Nanogram/Milliliter at Day 3.</measure>
    <time_frame>Day 3</time_frame>
    <description>Testosterone levels checked at Day 3 to determine if the reduction in testosterone level occurs rapidly after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to 50 Percent and 90 Percent Reduction in Prostate-Specific Antigen</measure>
    <time_frame>Day 0 (post dose) to Day 364</time_frame>
    <description>Median number of days after the first dose of Degarelix when the Prostate-Specific Antigen levels fell to 50 percent and 90 percent of the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to Prostate-Specific Antigen Progression</measure>
    <time_frame>Day 0 (post dose) to Day 364</time_frame>
    <description>Median days to prostate-specific antigen increase of &gt;= 50 percent and &gt;= 5 nanograms/milliliter compared to nadir on two consecutive visits at least 2 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Di-Hydrotestosterone Levels At Various Study Timepoints</measure>
    <time_frame>Baseline, Days 1, 3, 7, 14</time_frame>
    <description>Di-hydrotestosterone levels at baseline and days 1, 3, 7, 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Prostate-Specific Antigen Values at Various Study Timepoints</measure>
    <time_frame>Baseline, Days 3, 14, 28, 84, 364</time_frame>
    <description>Prostate-specific antigen levels at baseline and days 3, 14, 28, 84, and 364.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Luteinizing Hormone Levels at Various Study Timeframes</measure>
    <time_frame>Baseline, Days 1, 3, 7, 14</time_frame>
    <description>Luteinizing hormone levels at baseline, and days 1, 3, 7, and 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Testosterone Levels at Various Days During the Study</measure>
    <time_frame>Baseline, Days 1,3,7,14,364</time_frame>
    <description>Testosterone levels at baseline and days 1, 3, 7, 14 and 364</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Alanine Aminotransferase Values</measure>
    <time_frame>Day 1 through day 364</time_frame>
    <description>Participants whose alanine aminotransferase values were at levels above the normal range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Aspartate Aminotransferase Values</measure>
    <time_frame>Day 1 - 364</time_frame>
    <description>Participants with aspartate aminotransferase values that were above the normal range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Total Bilirubin Values</measure>
    <time_frame>Day 1 - 364</time_frame>
    <description>Participants with abnormal total bilirubin values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Markedly Abnormal Changes in Vital Signs or Body Weight</measure>
    <time_frame>Day 364</time_frame>
    <description>Vital sign and body weight values at the end of the trial are compared to baseline values. The table represents the number of participants in each group with normal baseline values and markedly abnormal end-of-study values.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Degarelix 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.</description>
    <arm_group_label>Degarelix 60mg</arm_group_label>
    <arm_group_label>Degarelix 80mg</arm_group_label>
    <other_name>FE200486</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each patient must meet the following inclusion criteria before entry into the study.

          -  Has given written consent prior to any study-related activity is performed (a
             study-related activity is defined as any procedure that would not have been performed
             during the normal management of the patient).

          -  Histologically confirmed adenocarcinoma of the prostate (all stages), in whom
             endocrine treatment (except for neoadjuvant hormonal therapy) is indicated. This
             includes patients with rising PSA after having received radical prostatectomy (removal
             of the entire prostate and seminal vesicles) or radiotherapy with curative intention.

          -  Male patient aged 18 years or over.

          -  Has a baseline testosterone above the lower limit of normal range.

          -  Has an ECOG (Eastern Co-operative Oncology Group) score equal to or less than 2.

          -  Has a PSA value of greater than or equal to 2ng/mL.

        Exclusion Criteria:

        Any patient meeting one or more of the following exclusion criteria will not be entered
        into the study.

          -  Previous or present hormonal management of prostate cancer (surgical castration or
             other hormonal manipulation, e.g. GnRH agonists, GnRH antagonists, antiandrogens,
             estrogens). However, patients having undergone neoadjuvant hormonal therapy in
             conjunction with prostatectomy or radiotherapy with curative intention may be included
             so long as the hormonal therapy did not exceed a total duration of 6 months and was
             terminated at least 6 months prior to the Screening Visit.

          -  Currently or recently (within the last 12 weeks preceding the Screening Visit) under
             treatment with any other drug modifying testosterone level or function.

          -  Is considered to be a candidate for curative therapy, i.e., radical prostatectomy or
             radiotherapy within 6 months from Screening Visit.

          -  Has a history of severe asthma (defined as a need for daily treatment with oral or
             inhalation steroids to control the asthma), anaphylactic reactions, angioedema,
             angioneurotic edema or Quincke's Edema.

          -  Has hypersensitivity towards any component of the investigational products (degarelix
             or mannitol).

          -  Has history of other cancer within the last 5 years except for prostate cancer and
             surgically removed basal or squamous cell carcinoma of the skin.

          -  Has elevated serum ALT level more than three times above upper level of normal range
             or serum total bilirubin level above one and a half times above upper level of normal
             range as measured by the laboratory at the Screening Visit.

          -  Has known or suspect hepatic disease of any sort. Patients with liver disease are not
             to be enrolled in this study.

          -  Has other clinically significant laboratory abnormalities, which in the judgment of
             the investigator would interfere with the participation of the patient in this study
             or evaluation of study results.

          -  Has a clinically significant disorder (other than prostate cancer) or any other
             condition, including excessive alcohol or drug abuse, which may interfere with trial
             participation or which may affect the conclusion of the study as judged by the
             investigator.

          -  Has a mental incapacity or language barriers precluding adequate understanding or
             cooperation.

          -  Has received an investigational drug within the last 12 weeks preceding Screening
             Visit.

          -  Has previously participated in any degarelix study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology Centers of Alabama</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alaska Clinical Research Center, LLC</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Urology Medical Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Orange County Medical Research Cnter</name>
      <address>
        <city>Laguna Woods,</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Clinical Research</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Clinical Research</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Clinical Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associate PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SW Florida Urological Associates</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Foundation for Healthcare Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RMD Clinical Reseach Institution LLC</name>
      <address>
        <city>Melrose Park</city>
        <state>Illinois</state>
        <zip>60160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Indiana Research, LLC</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Urology Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrenceville Urology</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Urology PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State College Urologic Association</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy Urological Research Institute</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont, Dept of Surgery</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Urology Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Jeffrey Frankel</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wyoming Research Foundation</name>
      <address>
        <city>Cheyenne</city>
        <state>Wyoming</state>
        <zip>82001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Interior Medical Research Corporation</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y2H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Cal Abdreau Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V1N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Can-Med Clinical Research, Inc.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Gary Steinhoff Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Professional Center</name>
      <address>
        <city>Kentville</city>
        <state>Nova Scotia</state>
        <zip>B4N4K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Male and Female Health and Research Centers</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brantford Urology Research</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <zip>N3R4N3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burlington Professional Care</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7N3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Female/Male Health Centres</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK; Degarelix Study Group. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol. 2008 Nov;180(5):1986-92. doi: 10.1016/j.juro.2008.07.033. Epub 2008 Sep 17.</citation>
    <PMID>18801505</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2005</study_first_posted>
  <results_first_submitted>January 22, 2009</results_first_submitted>
  <results_first_submitted_qc>March 19, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 20, 2009</results_first_posted>
  <last_update_submitted>December 15, 2011</last_update_submitted>
  <last_update_submitted_qc>December 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Androgen ablation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One hundred and seventy-six patients were screened to identify the one hundred and twenty-seven patients who were eligible for randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Degarelix 60mg</title>
          <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
        </group>
        <group group_id="P2">
          <title>Degarelix 80mg</title>
          <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63">Randomized and treated; Intent-to-treat population</participants>
                <participants group_id="P2" count="64">Randomized and treated; intent-to-treat population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inadequate testosterone suppression</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Elevated PSA levels</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Degarelix 60mg</title>
          <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
        </group>
        <group group_id="B2">
          <title>Degarelix 80mg</title>
          <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="127"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.8" spread="8.73"/>
                    <measurement group_id="B2" value="74.9" spread="9.55"/>
                    <measurement group_id="B3" value="74.9" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Curative Intent</title>
          <description>A curative intent of Yes refers to participants who have been castrated via radical prostatectomy or radiotherapy.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participant Counts by Gleason Score</title>
          <description>The Gleason score is a system of grading the aggressiveness of the prostate cancer and how fast it is likely to grow and spread. Scale is 2-10, with low numbers being the least aggressive and 10 being the most aggressive.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The Number of Participants at Each Stage of Prostate Cancer</title>
          <description>Prostate cancer stage was classified to describe the extent of cancer. Localized refers to tumors without involvement of lymph nodes or metastasis. Advanced localized can be larger tumors that may involve the lymph nodes but no metastasis. Metastatic are more advanced cancers that are spreading beyond the original tumor.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Localized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally advanced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not classifiable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body mass index is a measure of body fat based on height and weight.</description>
          <units>kilogram per square meter</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" spread="4.1" lower_limit="19.1" upper_limit="39.2"/>
                    <measurement group_id="B2" value="26.7" spread="3.98" lower_limit="16.9" upper_limit="36.4"/>
                    <measurement group_id="B3" value="27" spread="4.03" lower_limit="16.9" upper_limit="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Days Since Diagnosis of Prostate Cancer</title>
          <description>The number of days passed since a diagnosis of prostate cancer was made for each participant.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1213" spread="1597"/>
                    <measurement group_id="B2" value="1256" spread="1550"/>
                    <measurement group_id="B3" value="1234" spread="1568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Prostate-Specific Antigen</title>
          <description>Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. High PSA levels have a postive corrolation to prostate cancer.</description>
          <units>nanograms/milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.7" lower_limit="2.7" upper_limit="759"/>
                    <measurement group_id="B2" value="13.7" lower_limit="1.6" upper_limit="1942"/>
                    <measurement group_id="B3" value="13.4" lower_limit="1.6" upper_limit="1942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Testosterone level</title>
          <description>Testosterone is a steroid hormone from the androgen group, and the principal male sex hormone. This test measures the amount of testosterone in the blood. Androgen deprivation is used to manage prostate cancer.</description>
          <units>nanograms/milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" lower_limit="1.51" upper_limit="11"/>
                    <measurement group_id="B2" value="4.23" lower_limit="0.2" upper_limit="8.68"/>
                    <measurement group_id="B3" value="4.13" lower_limit="0.2" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Mean of Participants Weight in Kilograms</description>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83" spread="14.6"/>
                    <measurement group_id="B2" value="81.2" spread="12.7"/>
                    <measurement group_id="B3" value="82.1" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Testosterone &lt;=0.5 Nanogram/Milliliter From Day 28 to Day 364</title>
        <description>Number of participants with all testosterone values &lt;=0.5 nanogram/milliliter from Day 28 to Day 364</description>
        <time_frame>Day 28 to Day 364</time_frame>
        <population>ITT population of patients who completed the study and had testosterone &lt;=0.5 nanogram per milliliter at Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 60mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 80mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Testosterone &lt;=0.5 Nanogram/Milliliter From Day 28 to Day 364</title>
          <description>Number of participants with all testosterone values &lt;=0.5 nanogram/milliliter from Day 28 to Day 364</description>
          <population>ITT population of patients who completed the study and had testosterone &lt;=0.5 nanogram per milliliter at Day 28.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="73" upper_limit="94"/>
                    <measurement group_id="O2" value="41" lower_limit="64" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants</param_type>
            <param_value>86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>73</ci_lower_limit>
            <ci_upper_limit>94</ci_upper_limit>
            <estimate_desc>The 95% confidence interval was calculated by Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants</param_type>
            <param_value>77</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>64</ci_lower_limit>
            <ci_upper_limit>88</ci_upper_limit>
            <estimate_desc>The 95% confidence interval was calculated by Clopper-Pearson method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Testosterone &lt;= 0.5 Nanogram/Milliliter at Day 3.</title>
        <description>Testosterone levels checked at Day 3 to determine if the reduction in testosterone level occurs rapidly after dosing.</description>
        <time_frame>Day 3</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 60mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 80mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Testosterone &lt;= 0.5 Nanogram/Milliliter at Day 3.</title>
          <description>Testosterone levels checked at Day 3 to determine if the reduction in testosterone level occurs rapidly after dosing.</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="79" upper_limit="96"/>
                    <measurement group_id="O2" value="56" lower_limit="78" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants</param_type>
            <param_value>90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>79</ci_lower_limit>
            <ci_upper_limit>96</ci_upper_limit>
            <estimate_desc>The 95% confidence interval was calculated by Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants</param_type>
            <param_value>89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>78</ci_lower_limit>
            <ci_upper_limit>95</ci_upper_limit>
            <estimate_desc>The 95% confidence interval was calculated by Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8413</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Testosterone Level &lt;= 0.5 Nanogram/Milliliter From Day 28 to Day 364 for Participants With Testosterone &lt;= 0.5 Nanogram/Milliliter at Day 28</title>
        <description>Number of participants who maintained a testosterone level of &lt;=0.5 nanogram/milliliter from Day 28 to Day 364.</description>
        <time_frame>Day 28 - Day 364</time_frame>
        <population>ITT population of participants who completed the study and had a testosterone level of &lt;=0.5 nanogram per milliliter at Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 60mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 80mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Testosterone Level &lt;= 0.5 Nanogram/Milliliter From Day 28 to Day 364 for Participants With Testosterone &lt;= 0.5 Nanogram/Milliliter at Day 28</title>
          <description>Number of participants who maintained a testosterone level of &lt;=0.5 nanogram/milliliter from Day 28 to Day 364.</description>
          <population>ITT population of participants who completed the study and had a testosterone level of &lt;=0.5 nanogram per milliliter at Day 28.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="82" upper_limit="99"/>
                    <measurement group_id="O2" value="41" lower_limit="87" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants</param_type>
            <param_value>93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>82</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
            <estimate_desc>The 95% confidence interval was calculated by Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants</param_type>
            <param_value>98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>87</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>The 95% confidence interval was calculated by Clopper-Pearson method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to 50 Percent and 90 Percent Reduction in Prostate-Specific Antigen</title>
        <description>Median number of days after the first dose of Degarelix when the Prostate-Specific Antigen levels fell to 50 percent and 90 percent of the baseline value.</description>
        <time_frame>Day 0 (post dose) to Day 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 60mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 80mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Days to 50 Percent and 90 Percent Reduction in Prostate-Specific Antigen</title>
          <description>Median number of days after the first dose of Degarelix when the Prostate-Specific Antigen levels fell to 50 percent and 90 percent of the baseline value.</description>
          <population>ITT population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>50 percent reduction (n=59, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="3" upper_limit="84"/>
                    <measurement group_id="O2" value="14" lower_limit="1" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 percent reduction (n=45, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="28" upper_limit="168"/>
                    <measurement group_id="O2" value="56" lower_limit="14" upper_limit="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time to 50% reduction</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.904</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Days to 90% reduction</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.778</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to Prostate-Specific Antigen Progression</title>
        <description>Median days to prostate-specific antigen increase of &gt;= 50 percent and &gt;= 5 nanograms/milliliter compared to nadir on two consecutive visits at least 2 weeks apart.</description>
        <time_frame>Day 0 (post dose) to Day 364</time_frame>
        <population>ITT population. 5 patients in the 60 mg group and 4 patients in the 80 mg group had PSA progression.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 60mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 80mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Prostate-Specific Antigen Progression</title>
          <description>Median days to prostate-specific antigen increase of &gt;= 50 percent and &gt;= 5 nanograms/milliliter compared to nadir on two consecutive visits at least 2 weeks apart.</description>
          <population>ITT population. 5 patients in the 60 mg group and 4 patients in the 80 mg group had PSA progression.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" lower_limit="107" upper_limit="280"/>
                    <measurement group_id="O2" value="154" lower_limit="28" upper_limit="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Di-Hydrotestosterone Levels At Various Study Timepoints</title>
        <description>Di-hydrotestosterone levels at baseline and days 1, 3, 7, 14</description>
        <time_frame>Baseline, Days 1, 3, 7, 14</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 60mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 80mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Di-Hydrotestosterone Levels At Various Study Timepoints</title>
          <description>Di-hydrotestosterone levels at baseline and days 1, 3, 7, 14</description>
          <population>ITT population</population>
          <units>picogram / milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=63, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360" lower_limit="10" upper_limit="800"/>
                    <measurement group_id="O2" value="350" lower_limit="48" upper_limit="810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (n=62, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110" lower_limit="37" upper_limit="350"/>
                    <measurement group_id="O2" value="120" lower_limit="34" upper_limit="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=58, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" lower_limit="10" upper_limit="230"/>
                    <measurement group_id="O2" value="57" lower_limit="10" upper_limit="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=58, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="20" upper_limit="150"/>
                    <measurement group_id="O2" value="52" lower_limit="10" upper_limit="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="10" upper_limit="230"/>
                    <measurement group_id="O2" value="40" lower_limit="10" upper_limit="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Prostate-Specific Antigen Values at Various Study Timepoints</title>
        <description>Prostate-specific antigen levels at baseline and days 3, 14, 28, 84, and 364.</description>
        <time_frame>Baseline, Days 3, 14, 28, 84, 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 60mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 80mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Prostate-Specific Antigen Values at Various Study Timepoints</title>
          <description>Prostate-specific antigen levels at baseline and days 3, 14, 28, 84, and 364.</description>
          <population>ITT population</population>
          <units>nanogram / milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=63, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="2.7" upper_limit="759"/>
                    <measurement group_id="O2" value="13.7" lower_limit="1.6" upper_limit="1942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=60, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="2.1" upper_limit="1557"/>
                    <measurement group_id="O2" value="12.2" lower_limit="1.3" upper_limit="1206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=61, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="0.9" upper_limit="362"/>
                    <measurement group_id="O2" value="6.8" lower_limit="0.9" upper_limit="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=61, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="0.3" upper_limit="28.8"/>
                    <measurement group_id="O2" value="3.6" lower_limit="0.3" upper_limit="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n=57, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0" upper_limit="32.1"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0" upper_limit="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364 (n=42, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0" upper_limit="12.8"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0" upper_limit="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Luteinizing Hormone Levels at Various Study Timeframes</title>
        <description>Luteinizing hormone levels at baseline, and days 1, 3, 7, and 14.</description>
        <time_frame>Baseline, Days 1, 3, 7, 14</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 60mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 80mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Luteinizing Hormone Levels at Various Study Timeframes</title>
          <description>Luteinizing hormone levels at baseline, and days 1, 3, 7, and 14.</description>
          <population>ITT population</population>
          <units>international units / liter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=63, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" lower_limit="1.22" upper_limit="25"/>
                    <measurement group_id="O2" value="5.33" lower_limit="0.72" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (n=58, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.915" lower_limit="0.22" upper_limit="5.21"/>
                    <measurement group_id="O2" value="0.87" lower_limit="0.035" upper_limit="5.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=59, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" lower_limit="0.035" upper_limit="2.05"/>
                    <measurement group_id="O2" value="0.425" lower_limit="0.035" upper_limit="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=60, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="0.035" upper_limit="2.64"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.035" upper_limit="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=61, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.035" upper_limit="3.5"/>
                    <measurement group_id="O2" value="0.37" lower_limit="0.035" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Testosterone Levels at Various Days During the Study</title>
        <description>Testosterone levels at baseline and days 1, 3, 7, 14 and 364</description>
        <time_frame>Baseline, Days 1,3,7,14,364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 60mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 80mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Testosterone Levels at Various Days During the Study</title>
          <description>Testosterone levels at baseline and days 1, 3, 7, 14 and 364</description>
          <population>ITT population</population>
          <units>nanograms / milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=63, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="1.51" upper_limit="11"/>
                    <measurement group_id="O2" value="4.23" lower_limit="0.2" upper_limit="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (n=61, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" lower_limit="0.2" upper_limit="2.49"/>
                    <measurement group_id="O2" value="0.71" lower_limit="0.12" upper_limit="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=60, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" lower_limit="0.13" upper_limit="0.67"/>
                    <measurement group_id="O2" value="0.31" lower_limit="0.11" upper_limit="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=60, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.08" upper_limit="1.46"/>
                    <measurement group_id="O2" value="0.24" lower_limit="0.07" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=61, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.04" upper_limit="2.19"/>
                    <measurement group_id="O2" value="0.14" lower_limit="0.015" upper_limit="6.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364 (n=42, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.015" upper_limit="0.45"/>
                    <measurement group_id="O2" value="0.07" lower_limit="0.015" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Alanine Aminotransferase Values</title>
        <description>Participants whose alanine aminotransferase values were at levels above the normal range.</description>
        <time_frame>Day 1 through day 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 60mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 80mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Alanine Aminotransferase Values</title>
          <description>Participants whose alanine aminotransferase values were at levels above the normal range.</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt; upper limit and 3 times upper limit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total abnormal (&gt; upper limit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total normal (&lt;=upper limit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Aspartate Aminotransferase Values</title>
        <description>Participants with aspartate aminotransferase values that were above the normal range.</description>
        <time_frame>Day 1 - 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 60mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 80mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Aspartate Aminotransferase Values</title>
          <description>Participants with aspartate aminotransferase values that were above the normal range.</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt; 3 times upper limit - 5 times upper limit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; upper limit - 3 times upper limit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Abnormal (&gt; upper limit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Normal (&lt;= upper limit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Total Bilirubin Values</title>
        <description>Participants with abnormal total bilirubin values</description>
        <time_frame>Day 1 - 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 60mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 80mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Total Bilirubin Values</title>
          <description>Participants with abnormal total bilirubin values</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;2 times upper limit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.5 times upper limit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; upper limit - 1.5 times upper limit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total abnormal (&gt; upper limit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total normal (&lt;=upper limit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Markedly Abnormal Changes in Vital Signs or Body Weight</title>
        <description>Vital sign and body weight values at the end of the trial are compared to baseline values. The table represents the number of participants in each group with normal baseline values and markedly abnormal end-of-study values.</description>
        <time_frame>Day 364</time_frame>
        <population>ITT population. Diastolic blood pressure n=63,63 Pulse n=63,60 Systolic blood pressure n=63,64 Weight n=55,61</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 60mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 80mg</title>
            <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Markedly Abnormal Changes in Vital Signs or Body Weight</title>
          <description>Vital sign and body weight values at the end of the trial are compared to baseline values. The table represents the number of participants in each group with normal baseline values and markedly abnormal end-of-study values.</description>
          <population>ITT population. Diastolic blood pressure n=63,63 Pulse n=63,60 Systolic blood pressure n=63,64 Weight n=55,61</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diastolic blood pressure &lt;= 50 and decrease &gt;= 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure &gt;= 105 and increase &gt;= 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse &lt;=50 and decrease of &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse &gt;=120 and increase of &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure &lt;=90 and decrease &gt;=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure &gt;=180 and increase &gt;=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight decrease of &gt;=7 percent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight increase of &gt;= 7 percent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Degarelix 60mg</title>
          <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.</description>
        </group>
        <group group_id="E2">
          <title>Degarelix 80mg</title>
          <description>Initial dose of 200 milligrams of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9"/>
                <counts group_id="E2" subjects_affected="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis radiation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 7.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55"/>
                <counts group_id="E2" subjects_affected="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="63"/>
                <counts group_id="E2" events="37" subjects_affected="31" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of ublication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ferring Pharmaceuticals</name_or_title>
      <organization>Clinical Development Support</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

